Daiichi Sankyo Company Limited http://www.alacrastore.com/company-snapshot/Daiichi_Sankyo_Company_Limited-3706499 Tuesday, October 14, 2008 9:27:13 AM 3706499 Daiichi Sankyo Company Limited en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/KYO-0001-28562600newstex/KYO-0001-28562600xml TOKYO, Oct. #, #### (Kyodo News International delivered by Newstex) -- Shionogi & Co. said Monday that it successfully completed its friendly tender offer for U.S. pharmaceutical company Sciele Pharma (NASDAQ:SCRX) Inc. on Friday,...040000000400200004002006040160000401600510/6/2008 5:25:53 AM1800000018016000190000001900200019002004Kyodo News InternationalKYO-0001-28562600DAIICHI SANKYO CO LTDSCIELE PHARMA INC.DSKYYSCRXNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/KYO-0001-28524005newstex/KYO-0001-28524005xml NEW DELHI, Oct. #, #### (Kyodo News International delivered by Newstex) -- The Indian government has approved the acquisition of Indian drug company Ranbaxy Laboratories Ltd. by Japanese drug company Daiichi Sankyo Co. (OOTC:DSKYY)...040000000400200004002006040160000401600510/3/2008 9:21:41 AM180000001801600019000000190030001900200019002004Kyodo News InternationalKYO-0001-28524005DAIICHI SANKYO CO LTDDSKYYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-28195494newstex/PRN-0001-28195494xml Sep. ##, #### (Canada NewsWire Group delivered by Newstex) -- MISSISSAUGA, ON, Sept. ## /CNW/ -- YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products...0700000007005000040000000400200004002006040160000401600104016018040160030401604707014000070140080701401207001000070010040700300007003001020000000200200002002004020020059/19/2008 6:19:40 PM1800000018004000190000001900100019002000190020041900201319002007190020121900200919002016Canada NewsWire GroupPRN-0001-28195494DAIICHI SANKYO CO LTDYM BIOSCIENCES INCDSKYYYMYMINewsNewstexhttp://www.alacrastore.com/storecontent/bir/1322013bir/1322013normDaiichi Sankyo Company Ltd.JapanManufacturing: Manufacturing and marketing of pharmaceuticals.283428192833284428692879512267193254123251313251883253203254113256204242105511129IL45689/9/2008 6:17:52 AM1322013Company Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/newstex/KYO-0001-27802159newstex/KYO-0001-27802159xml TOKYO, Sep. #, #### (Kyodo News International delivered by Newstex) -- Japanese drug manufacturer Shionogi & Co. said Monday it will launch a $#.# billion friendly offer for shares in U.S. pharmaceutical company Sciele Pharma (NASDAQ:SCRX)...0400000004002000040020069/1/2008 3:26:46 AM1800000018016000Kyodo News InternationalKYO-0001-27802159DAIICHI SANKYO CO LTDSCIELE PHARMA INC.DSKYYSCRXNewsNewstexGERMANY - Daiichi Sankyo Deutschland GmbH, a wholly-owned unit of Daiichi Sankyo Co of Japan agreed to acquire Primary Care External Sales Activities of Merck Pharma GmbH, a Darmstadt-based manufacturer and developer of pharmaceuticals, and subsidiary of Merck KGaA. Terms were not disclosed.7/22/2008 6:51:10 PM23778A58928Z23186L589339Daiichi Sankyo Deutschland GmbHMerck Pharma GmbH-Primary Care External Sales ActivitiesDaiichi Sankyo Co LtdMerck KGaAhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Daiichi_Sankyo_Deutschland_Gmb_acquires_Merck_Pharma_GmbH_Primary_Care_from_Merck_KGaA-1997271040sdc/19972710401997271040Copyright © 2008, Thomson Financial, All Rights ReservedDrugsGermanyPharmaceutical preparations2834FFForeignSubsidiary2834:Pharmaceutical preparations8731:Commercial physical and biological research2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec5122:Drugs, drug proprietaries, and druggists' sundries5191:Farm suppliesBusiness ServicesGermanyManagement consulting services8742FFForeignSubsidiary1029794001Mnfr,whl pharmMnfr,whl pharmUnspecifiedAssets1029801001Jul 22 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.00000Daiichi Sankyo DeutschlandGmbH, located in Munich,Germany, manufactures anddevelops pharmaceuticals. Itwas founded in 1985.Daiichi Sankyo Deutschland GmbH, located in Munich, Germany,manufactures and develops pharmaceuticals. It was founded in1985.Daiichi Sankyo Deutschland GmbH, located in Munich, Germany, manufactures and develops pharmaceuticals. It was founded in 1985.1.000002.000003.000004.000005.00000Primary Care External SalesActivities of Merck PharmaGmbH, located in Darmstadt,Germany, provides salesrelated services.Primary Care External Sales Activities of Merck Pharma GmbH,located in Darmstadt, Germany, provides sales relatedservices.Primary Care External Sales Activities of Merck Pharma GmbH, located in Darmstadt, Germany, provides sales related services.0.000000.000000.000000.00000Y16 Jul 08Wed, 16 Jul 2008 00:00:00 ESTDate Announced: 07/16/2008Date Effective:Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.0000000.000000.0000000.000000.000000.000000.000000.000000.0000000.00000N0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.00000GERMANY - Daiichi SankyoDeutschland GmbH, awholly-owned unit of DaiichiSankyo Co of Japan agreed toacquire Primary Care ExternalSales Activities of MerckPharma GmbH, a Darmstadt-basedmanufacturer and developer ofpharmaceuticals, andsubsidiary of Merck KGaA.Terms were not disclosed.GERMANY - Daiichi Sankyo Deutschland GmbH, a wholly-owned unit of Daiichi Sankyo Co of Japan agreed to acquire Primary Care External Sales Activities of Merck Pharma GmbH, a Darmstadt-based manufacturer and developer of pharmaceuticals, and subsidiary of Merck KGaA. Terms were not disclosed.GERMANY - Daiichi Sankyo Deutschland GmbH, a wholly-owned unit of Daiichi Sankyo Co ofJapan agreed to acquire Primary Care External Sales Activities of Merck Pharma GmbH, aDarmstadt-based manufacturer and developer of pharmaceuticals, and subsidiary of MerckKGaA. Terms were not disclosed.GERMANY - Daiichi Sankyo Deutschland GmbH, a wholly-owned unit of Daiichi Sankyo Co of Japan agreed to acquire Primary Care External Sales Activities of Merck Pharma GmbH, a Darmstadt-basedmanufacturer and developer of pharmaceuticals, and subsidiary of Merck KGaA. Terms were not disclosed.GERMANY - Daiichi Sankyo Deutschland GmbH, a wholly-owned unit of Daiichi Sankyo Co of Japan agreed to acquire Primary Care ExternalSales Activities of Merck Pharma GmbH, a Darmstadt-based manufacturer and developer of pharmaceuticals, and subsidiary of Merck KGaA.Terms were not disclosed.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000007319:Advertising, nec8742:Management consulting services5310002Tokyo 1Japan2834ForeignPublic45682833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5122:Drugs, drug proprietaries, and druggists' sundries6719:Offices of holding companies, nec136805001FrankfurtGermany2834ForeignPublicMRK0.000000.000000.000000.00000Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/moodys/PR_157137_808782507moodys/PR_157137_808782507htmlGlobal Credit Research Rating Action ## JUN #### Rating Action: Daiichi Sankyo Company, Limited Moody's places Daiichi Sankyo on review for possible downgrade Tokyo, June ##, #### -- Moody's Investors Service has placed the Aa# issuer...6/13/2008 12:26:25 AMhtmlDaiichi Sankyo Company, LimitedDaiichi Sankyo Company, Limited808782507150.0000NewsRating ActionPR_157137_808782507Credit & Investment ResearchMoody's Global Credit ResearchINDIA - Daiichi Sankyo Co Ltd (DS) agreed to acquire ordinary shares and warrants convertible into a ##.##%, or ###.### mil new ordinary shares, in Ranbaxy Laboratories Ltd (RL), a prescription pharmaceuticals manufacturer, from the Singh family, for ### Indian rupees (#,###.### Japanese yen/$##.### US) per share, or a total value of ###.### bil rupees (###.### bil yen/$#.### bil), in a privately negotiated transaction. Concurrently, DS planned to launch a mandatory tender offer to raise its interest to ##.##% from ##.##% by acquiring a further ##% stake, or ##.### mil ordinary shares, in RL. Subsequently, DS planned to launch a tender offer to acquire a ##% stake, or #.## mil ordinary shares, in Zenotech Laboratories Ltd.6/12/2008 3:24:21 PM23186L75188123186L751881Daiichi Sankyo Co LtdRanbaxy Laboratories LtdDaiichi Sankyo Co LtdRanbaxy Laboratories Ltdhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Daiichi_Sankyo_Co_Ltd_acquires_a_minority_stake_in_Ranbaxy_Laboratories_Ltd-1985614040sdc/19856140401985614040Copyright © 2008, Thomson Financial, All Rights ReservedTokyo 1DrugsJapanPharmaceutical preparations2834FFForeignPublic45682833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec5122:Drugs, drug proprietaries, and druggists' sundries5191:Farm supplies2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec5122:Drugs, drug proprietaries, and druggists' sundries5191:Farm suppliesBombayDrugsIndiaPharmaceutical preparations2834FFForeignPublic5003595310002Mnfr,whl pharmMnfr prescription pharmCashCash OnlyNewly Issued Ord ShOrdinary ShareWarrants150047001Jun 12 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.00000Daiichi Sankyo Co Ltd,headquartered in Tokyo, Japan,manufactures and distributespharmaceuticals, medicalsurgical supplies,agrochemical, foods,cosmetics, synthetic andindustrial chemicals andrelated products. Operationsare carried out through thefollowing sectors:pharmaceuticals and others.The pharmaceuticals includegeneral medicines. The otherdivision deals with foods suchas foods and food additives,agriculture related productssuch as insecticides andothers such as chemicals,animal medicines, feedssundries and car leasing. Thecompany was founded in 2005.Daiichi Sankyo Co Ltd, headquartered in Tokyo, Japan,manufactures and distributes pharmaceuticals, medicalsurgical supplies, agrochemical, foods, cosmetics, syntheticand industrial chemicals and related products. Operationsare carried out through the following sectors:pharmaceuticals and others. The pharmaceuticals includegeneral medicines. The other division deals with foods suchas foods and food additives, agriculture related productssuch as insecticides and others such as chemicals, animalmedicines, feeds sundries and car leasing. The company wasfounded in 2005.Daiichi Sankyo Co Ltd, headquartered in Tokyo, Japan, manufactures and distributes pharmaceuticals, medical surgical supplies, agrochemical, foods, cosmetics, synthetic and industrial chemicals and related products. Operations are carried out through the following sectors: pharmaceuticals and others. The pharmaceuticals include general medicines. The other division deals with foods such as foods and food additives, agriculture related products such as insecticides and others such as chemicals, animal medicines, feeds sundries and car leasing. The company was founded in 2005.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.00000Ranbaxy Laboratories Ltd,located in Gurgaon, India,manufactures and wholesalesactive pharmaceutical andtherapies for finished dosageformulations andpharmaceutical ingredients. Ithas manufacturing facilitiesin eight countries. Founded in1961.Ranbaxy Laboratories Ltd, located in Gurgaon, India,manufactures and wholesales active pharmaceutical andtherapies for finished dosage formulations andpharmaceutical ingredients. It has manufacturing facilitiesin eight countries. Founded in 1961.Ranbaxy Laboratories Ltd, located in Gurgaon, India, manufactures and wholesales active pharmaceutical and therapies for finished dosage formulations and pharmaceutical ingredients. It has manufacturing facilities in eight countries. Founded in 1961.0.000000.000000.00000443.25000YIndian Rupee11 Jun 08Wed, 11 Jun 2008 00:00:00 ESTDate Announced: 06/11/2008Date Effective:Acq. Part. Int.Neutral0.000000.000000.000000.000000.00000737.00000Price/Share0.00000147421 Indian Rupee147421.08600275014.24700147421 Indian Rupee147421.086000.000000.0000017.2060017.20600147421.08600147421 Indian Rupee0.02300N1761.718000.000000.000000.000000.000000.000003441.693003441.693000.000000.000000.000000.000000.000000.000000.0000045.128000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.00000INDIA - Daiichi Sankyo Co Ltd(DS) agreed to acquireordinary shares and warrantsconvertible into a 45.13%, or200.029 mil new ordinaryshares, in RanbaxyLaboratories Ltd (RL), aprescription pharmaceuticalsmanufacturer, from the Singhfamily, for 737 Indian rupees(1,847.525 Japaneseyen/$17.206 US) per share, ora total value of 147.421 bilrupees (369.558 bil yen/$3.442bil), in a privatelynegotiated transaction.Concurrently, DS planned tolaunch a mandatory tenderoffer to raise its interest to65.13% from 45.13% byacquiring a further 20% stake,or 88.649 mil ordinary shares,in RL. Subsequently, DSplanned to launch a tenderoffer to acquire a 20% stake,or 6.86 mil ordinary shares,in Zenotech Laboratories Ltd.INDIA - Daiichi Sankyo Co Ltd (DS) agreed to acquire ordinary shares and warrants convertible into a 45.13%, or 200.029 mil new ordinary shares, in Ranbaxy Laboratories Ltd (RL), a prescription pharmaceuticals manufacturer, from the Singh family, for 737 Indian rupees (1,847.525 Japanese yen/$17.206 US) per share, or a total value of 147.421 bil rupees (369.558 bil yen/$3.442 bil), in a privately negotiated transaction. Concurrently, DS planned to launch a mandatory tender offer to raise its interest to 65.13% from 45.13% by acquiring a further 20% stake, or 88.649 mil ordinary shares, in RL. Subsequently, DS planned to launch a tender offer to acquire a 20% stake, or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd.INDIA - Daiichi Sankyo Co Ltd (DS) agreed to acquire ordinary shares and warrantsconvertible into a 45.13%, or 200.029 mil new ordinary shares, in Ranbaxy Laboratories Ltd(RL), a prescription pharmaceuticals manufacturer, from the Singh family, for 737 Indianrupees (1,847.525 Japanese yen/$17.206 US) per share, or a total value of 147.421 bilrupees (369.558 bil yen/$3.442 bil), in a privately negotiated transaction. Concurrently,DS planned to launch a mandatory tender offer to raise its interest to 65.13% from 45.13%by acquiring a further 20% stake, or 88.649 mil ordinary shares, in RL. Subsequently, DSplanned to launch a tender offer to acquire a 20% stake, or 6.86 mil ordinary shares, inZenotech Laboratories Ltd.INDIA - Daiichi Sankyo Co Ltd (DS) agreed to acquire ordinary shares and warrants convertible into a 45.13%, or 200.029 mil new ordinary shares, in Ranbaxy Laboratories Ltd (RL), a prescriptionpharmaceuticals manufacturer, from the Singh family, for 737 Indian rupees (1,847.525 Japanese yen/$17.206 US) per share, or a total value of 147.421 bil rupees (369.558 bil yen/$3.442 bil), in aprivately negotiated transaction. Concurrently, DS planned to launch a mandatory tender offer to raise its interest to 65.13% from 45.13% by acquiring a further 20% stake, or 88.649 mil ordinaryshares, in RL. Subsequently, DS planned to launch a tender offer to acquire a 20% stake, or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd.INDIA - Daiichi Sankyo Co Ltd (DS) agreed to acquire ordinary shares and warrants convertible into a 45.13%, or 200.029 mil new ordinaryshares, in Ranbaxy Laboratories Ltd (RL), a prescription pharmaceuticals manufacturer, from the Singh family, for 737 Indian rupees(1,847.525 Japanese yen/$17.206 US) per share, or a total value of 147.421 bil rupees (369.558 bil yen/$3.442 bil), in a privatelynegotiated transaction. Concurrently, DS planned to launch a mandatory tender offer to raise its interest to 65.13% from 45.13% byacquiring a further 20% stake, or 88.649 mil ordinary shares, in RL. Subsequently, DS planned to launch a tender offer to acquire a 20%stake, or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5310002Tokyo 1Japan2834ForeignPublic45682833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances150047001BombayIndia2834ForeignPublic5003593441.69300147421.086003441.693001761.71800Deal InformationTF Mergers & AcquisitionsINDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a mandatory tender offer to raise its interest to ##.##% from ##.##% by acquiring a further ##% stake, or ##.### mil ordinary shares, in Ranbaxy Laboratories Ltd (RL), a prescription pharmaceuticals manufacturer, for ### Indian rupees (#,###.### Japanese yen/$##.### US) per share, or a total value of ##.### bil rupees (###.### bil yen/$#.### bil). Concurrently, DS agreed to acquire ordinary shares and warrants convertible into a ##.##%, or ###.### mil new ordinary shares, in RL. Subsequently, DS planned to launch a tender offer to acquire a ##% stake, or #.## mil ordinary shares, in Zenotech Laboratories Ltd.6/12/2008 3:24:21 PM23186L75188123186L751881Daiichi Sankyo Co LtdRanbaxy Laboratories LtdDaiichi Sankyo Co LtdRanbaxy Laboratories Ltdhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Daiichi_Sankyo_Co_Ltd_acquires_Ranbaxy_Laboratories_Ltd-1985615040sdc/19856150401985615040Copyright © 2008, Thomson Financial, All Rights ReservedTokyo 1DrugsJapanPharmaceutical preparations2834FFForeignPublic45682833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec5122:Drugs, drug proprietaries, and druggists' sundries5191:Farm supplies2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec5122:Drugs, drug proprietaries, and druggists' sundries5191:Farm suppliesBombayDrugsIndiaPharmaceutical preparations2834FFForeignPublic5003595310002Mnfr,whl pharmMnfr prescription pharmCashCash OnlyOrdinary Share150047001Jun 12 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.00000Daiichi Sankyo Co Ltd,headquartered in Tokyo, Japan,manufactures and distributespharmaceuticals, medicalsurgical supplies,agrochemical, foods,cosmetics, synthetic andindustrial chemicals andrelated products. Operationsare carried out through thefollowing sectors:pharmaceuticals and others.The pharmaceuticals includegeneral medicines. The otherdivision deals with foods suchas foods and food additives,agriculture related productssuch as insecticides andothers such as chemicals,animal medicines, feedssundries and car leasing. Thecompany was founded in 2005.Daiichi Sankyo Co Ltd, headquartered in Tokyo, Japan,manufactures and distributes pharmaceuticals, medicalsurgical supplies, agrochemical, foods, cosmetics, syntheticand industrial chemicals and related products. Operationsare carried out through the following sectors:pharmaceuticals and others. The pharmaceuticals includegeneral medicines. The other division deals with foods suchas foods and food additives, agriculture related productssuch as insecticides and others such as chemicals, animalmedicines, feeds sundries and car leasing. The company wasfounded in 2005.Daiichi Sankyo Co Ltd, headquartered in Tokyo, Japan, manufactures and distributes pharmaceuticals, medical surgical supplies, agrochemical, foods, cosmetics, synthetic and industrial chemicals and related products. Operations are carried out through the following sectors: pharmaceuticals and others. The pharmaceuticals include general medicines. The other division deals with foods such as foods and food additives, agriculture related products such as insecticides and others such as chemicals, animal medicines, feeds sundries and car leasing. The company was founded in 2005.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.00000Ranbaxy Laboratories Ltd,located in Gurgaon, India,manufactures and wholesalesactive pharmaceutical andtherapies for finished dosageformulations andpharmaceutical ingredients. Ithas manufacturing facilitiesin eight countries. Founded in1961.Ranbaxy Laboratories Ltd, located in Gurgaon, India,manufactures and wholesales active pharmaceutical andtherapies for finished dosage formulations andpharmaceutical ingredients. It has manufacturing facilitiesin eight countries. Founded in 1961.Ranbaxy Laboratories Ltd, located in Gurgaon, India, manufactures and wholesales active pharmaceutical and therapies for finished dosage formulations and pharmaceutical ingredients. It has manufacturing facilities in eight countries. Founded in 1961.0.000000.000000.00000443.25000YIndian Rupee11 Jun 08Wed, 11 Jun 2008 00:00:00 ESTDate Announced: 06/11/2008Date Effective:Acq. Maj. Int.Friendly0.000000.000000.000000.000000.00000737.00000Price/Share0.0000065334.5 Indian Rupee65334.46900326672.3430065334.5 Indian Rupee65334.469000.000000.0000017.2060017.2060065334.4690065334.5 Indian Rupee0.02300N780.763000.000000.000000.000000.000000.000001525.299001525.299000.000000.000000.000000.000000.000000.0000045.1280020.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.00000INDIA - Daiichi Sankyo Co Ltd(DS) planned to launch amandatory tender offer toraise its interest to 65.13%from 45.13% by acquiring afurther 20% stake, or 88.649mil ordinary shares, inRanbaxy Laboratories Ltd (RL),a prescription pharmaceuticalsmanufacturer, for 737 Indianrupees (1,847.525 Japaneseyen/$17.206 US) per share, ora total value of 65.334 bilrupees (163.782 bil yen/$1.525bil). Concurrently, DS agreedto acquire ordinary shares andwarrants convertible into a45.13%, or 200.029 mil newordinary shares, in RL.Subsequently, DS planned tolaunch a tender offer toacquire a 20% stake, or 6.86mil ordinary shares, inZenotech Laboratories Ltd.INDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a mandatory tender offer to raise its interest to 65.13% from 45.13% by acquiring a further 20% stake, or 88.649 mil ordinary shares, in Ranbaxy Laboratories Ltd (RL), a prescription pharmaceuticals manufacturer, for 737 Indian rupees (1,847.525 Japanese yen/$17.206 US) per share, or a total value of 65.334 bil rupees (163.782 bil yen/$1.525 bil). Concurrently, DS agreed to acquire ordinary shares and warrants convertible into a 45.13%, or 200.029 mil new ordinary shares, in RL. Subsequently, DS planned to launch a tender offer to acquire a 20% stake, or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd.INDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a mandatory tender offer to raise itsinterest to 65.13% from 45.13% by acquiring a further 20% stake, or 88.649 mil ordinaryshares, in Ranbaxy Laboratories Ltd (RL), a prescription pharmaceuticals manufacturer, for737 Indian rupees (1,847.525 Japanese yen/$17.206 US) per share, or a total value of65.334 bil rupees (163.782 bil yen/$1.525 bil). Concurrently, DS agreed to acquireordinary shares and warrants convertible into a 45.13%, or 200.029 mil new ordinaryshares, in RL. Subsequently, DS planned to launch a tender offer to acquire a 20% stake,or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd.INDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a mandatory tender offer to raise its interest to 65.13% from 45.13% by acquiring a further 20% stake, or 88.649 mil ordinary shares, in RanbaxyLaboratories Ltd (RL), a prescription pharmaceuticals manufacturer, for 737 Indian rupees (1,847.525 Japanese yen/$17.206 US) per share, or a total value of 65.334 bil rupees (163.782 bil yen/$1.525bil). Concurrently, DS agreed to acquire ordinary shares and warrants convertible into a 45.13%, or 200.029 mil new ordinary shares, in RL. Subsequently, DS planned to launch a tender offer to acquirea 20% stake, or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd.INDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a mandatory tender offer to raise its interest to 65.13% from 45.13% by acquiring afurther 20% stake, or 88.649 mil ordinary shares, in Ranbaxy Laboratories Ltd (RL), a prescription pharmaceuticals manufacturer, for 737Indian rupees (1,847.525 Japanese yen/$17.206 US) per share, or a total value of 65.334 bil rupees (163.782 bil yen/$1.525 bil).Concurrently, DS agreed to acquire ordinary shares and warrants convertible into a 45.13%, or 200.029 mil new ordinary shares, in RL.Subsequently, DS planned to launch a tender offer to acquire a 20% stake, or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd.Intended0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Intended-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5310002Tokyo 1Japan2834ForeignPublic45682833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances150047001BombayIndia2834ForeignPublic5003591525.2990065334.469001525.29900780.76300Deal InformationTF Mergers & AcquisitionsINDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a tender offer to acquire a ##% stake, or #.## mil ordinary shares, in Zenotech Laboratories Ltd, a pharmaceuticals manufacturer and wholesaler. Concurrently, DS agreed to acquire ordinary shares and warrants convertible into a ##.##%, or ###.### mil new ordinary shares, in Ranbaxy Laboratories Ltd (RL). Subsequently, DS planned to launch a mandatory tender offer to raise its interest to ##.##% from ##.##% by acquiring a further ##% stake, or ##.### mil ordinary shares, in RL.6/12/2008 3:24:21 PM23186L98827W23186L98827WDaiichi Sankyo Co LtdZenotech Laboratories LtdDaiichi Sankyo Co LtdZenotech Laboratories Ltdhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Daiichi_Sankyo_Co_Ltd_acquires_a_minority_stake_in_Zenotech_Laboratories_Ltd-1985616040sdc/19856160401985616040Copyright © 2008, Thomson Financial, All Rights ReservedTokyo 1DrugsJapanPharmaceutical preparations2834FFForeignPublic45682833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec5122:Drugs, drug proprietaries, and druggists' sundries5191:Farm supplies2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec5122:Drugs, drug proprietaries, and druggists' sundries5191:Farm suppliesBombayDrugsIndiaPharmaceutical preparations2834FFForeignPublic5320395310002Mnfr,whl pharmMnfr,whl pharmUnspecifiedOrdinary Share395276003Jun 12 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.00000Daiichi Sankyo Co Ltd,headquartered in Tokyo, Japan,manufactures and distributespharmaceuticals, medicalsurgical supplies,agrochemical, foods,cosmetics, synthetic andindustrial chemicals andrelated products. Operationsare carried out through thefollowing sectors:pharmaceuticals and others.The pharmaceuticals includegeneral medicines. The otherdivision deals with foods suchas foods and food additives,agriculture related productssuch as insecticides andothers such as chemicals,animal medicines, feedssundries and car leasing. Thecompany was founded in 2005.Daiichi Sankyo Co Ltd, headquartered in Tokyo, Japan,manufactures and distributes pharmaceuticals, medicalsurgical supplies, agrochemical, foods, cosmetics, syntheticand industrial chemicals and related products. Operationsare carried out through the following sectors:pharmaceuticals and others. The pharmaceuticals includegeneral medicines. The other division deals with foods suchas foods and food additives, agriculture related productssuch as insecticides and others such as chemicals, animalmedicines, feeds sundries and car leasing. The company wasfounded in 2005.Daiichi Sankyo Co Ltd, headquartered in Tokyo, Japan, manufactures and distributes pharmaceuticals, medical surgical supplies, agrochemical, foods, cosmetics, synthetic and industrial chemicals and related products. Operations are carried out through the following sectors: pharmaceuticals and others. The pharmaceuticals include general medicines. The other division deals with foods such as foods and food additives, agriculture related products such as insecticides and others such as chemicals, animal medicines, feeds sundries and car leasing. The company was founded in 2005.1.000002.000003.000004.000005.000006.000007.000008.00000Zenotech Laboratories Ltd,located in Hyderabad, India,manufactures and wholesalespharmaceuticals. The Groupoperates at Brazil, Nigeria,U.S.A. and other countries.The company was founded in1989.Zenotech Laboratories Ltd, located in Hyderabad, India,manufactures and wholesales pharmaceuticals. The Groupoperates at Brazil, Nigeria, U.S.A. and other countries. Thecompany was founded in 1989.Zenotech Laboratories Ltd, located in Hyderabad, India, manufactures and wholesales pharmaceuticals. The Group operates at Brazil, Nigeria, U.S.A. and other countries. The company was founded in 1989.0.000000.000000.0000034.30000Y11 Jun 08Wed, 11 Jun 2008 00:00:00 ESTDate Announced: 06/11/2008Date Effective:Acq. Part. Int.Friendly0.000000.000000.000000.000000.000000.00000Price/Share0.0000000.000000.0000000.000000.000000.000000.000000.000000.0000000.00000N0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.0000020.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.00000INDIA - Daiichi Sankyo Co Ltd(DS) planned to launch atender offer to acquire a 20%stake, or 6.86 mil ordinaryshares, in ZenotechLaboratories Ltd, apharmaceuticals manufacturerand wholesaler. Concurrently,DS agreed to acquire ordinaryshares and warrantsconvertible into a 45.13%, or200.029 mil new ordinaryshares, in RanbaxyLaboratories Ltd (RL).Subsequently, DS planned tolaunch a mandatory tenderoffer to raise its interest to65.13% from 45.13% byacquiring a further 20% stake,or 88.649 mil ordinary shares,in RL.INDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a tender offer to acquire a 20% stake, or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd, a pharmaceuticals manufacturer and wholesaler. Concurrently, DS agreed to acquire ordinary shares and warrants convertible into a 45.13%, or 200.029 mil new ordinary shares, in Ranbaxy Laboratories Ltd (RL). Subsequently, DS planned to launch a mandatory tender offer to raise its interest to 65.13% from 45.13% by acquiring a further 20% stake, or 88.649 mil ordinary shares, in RL.INDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a tender offer to acquire a 20%stake, or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd, a pharmaceuticalsmanufacturer and wholesaler. Concurrently, DS agreed to acquire ordinary shares andwarrants convertible into a 45.13%, or 200.029 mil new ordinary shares, in RanbaxyLaboratories Ltd (RL). Subsequently, DS planned to launch a mandatory tender offer toraise its interest to 65.13% from 45.13% by acquiring a further 20% stake, or 88.649 milordinary shares, in RL.INDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a tender offer to acquire a 20% stake, or 6.86 mil ordinary shares, in Zenotech Laboratories Ltd, a pharmaceuticals manufacturer and wholesaler.Concurrently, DS agreed to acquire ordinary shares and warrants convertible into a 45.13%, or 200.029 mil new ordinary shares, in Ranbaxy Laboratories Ltd (RL). Subsequently, DS planned to launch amandatory tender offer to raise its interest to 65.13% from 45.13% by acquiring a further 20% stake, or 88.649 mil ordinary shares, in RL.INDIA - Daiichi Sankyo Co Ltd (DS) planned to launch a tender offer to acquire a 20% stake, or 6.86 mil ordinary shares, in ZenotechLaboratories Ltd, a pharmaceuticals manufacturer and wholesaler. Concurrently, DS agreed to acquire ordinary shares and warrantsconvertible into a 45.13%, or 200.029 mil new ordinary shares, in Ranbaxy Laboratories Ltd (RL). Subsequently, DS planned to launch amandatory tender offer to raise its interest to 65.13% from 45.13% by acquiring a further 20% stake, or 88.649 mil ordinary shares, inRL.Intended0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Intended-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5122:Drugs, drug proprietaries, and druggists' sundries5912:Drug stores and proprietary stores8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations5310002Tokyo 1Japan2834ForeignPublic45682834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5122:Drugs, drug proprietaries, and druggists' sundries5912:Drug stores and proprietary stores8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations395276003BombayIndia2834ForeignPublic5320390.000000.000000.000000.00000Deal InformationTF Mergers & AcquisitionsGERMANY - Daiichi Sankyo Co Ltd of Japan agreed to acquire the entire share capital of U# Pharma AG, a Martinsried-based biotechnology and pharmaceutical company, for ### mil euros ($ ###.### mil US) in cash. The transaction was subject to regulatory approval and customary closing conditions.5/22/2008 3:36:35 PM23186L91884W23186L91884WDaiichi Sankyo Co LtdU3 Pharma AGDaiichi Sankyo Co LtdU3 Pharma AGhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Daiichi_Sankyo_Co_Ltd_acquires_U3_Pharma_AG-1979728040sdc/19797280401979728040Copyright © 2008, Thomson Financial, All Rights ReservedTokyo 1DrugsJapanPharmaceutical preparations2834FFForeignPublic45682833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec5122:Drugs, drug proprietaries, and druggists' sundries5191:Farm supplies2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec5122:Drugs, drug proprietaries, and druggists' sundries5191:Farm suppliesDrugsGermanyBiological products, except diagnostic substances2836FFForeignPrivate5310002Mnfr,whl pharmBiotech,pharm coCashCash OnlyStock851270001May 22 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.00000The Group's principalactivities are the manufactureand distribution ofpharmaceuticals, medicalsurgical supplies,agrochemical, foods,cosmetics, synthetic andindustrial chemicals andrelated products. Operationsare carried out through thefollowing sectors:Pharmaceuticals and Others.The Pharmaceuticals includegeneral medicines. The otherdivision deals with foods suchas foods and food additives,agriculture related productssuch as insecticides andothers such as chemicals,animal medicines, feedssundries and car leasing.The Group's principal activities are the manufacture anddistribution of pharmaceuticals, medical surgical supplies,agrochemical, foods, cosmetics, synthetic and industrialchemicals and related products. Operations are carried outthrough the following sectors: Pharmaceuticals and Others.The Pharmaceuticals include general medicines. The otherdivision deals with foods such as foods and food additives,agriculture related products such as insecticides and otherssuch as chemicals, animal medicines, feeds sundries and carleasing.The Group's principal activities are the manufacture and distribution of pharmaceuticals, medical surgical supplies, agrochemical, foods, cosmetics, synthetic and industrial chemicals and related products. Operations are carried out through the following sectors: Pharmaceuticals and Others. The Pharmaceuticals include general medicines. The other division deals with foods such as foods and food additives, agriculture related products such as insecticides and others such as chemicals, animal medicines, feeds sundries and car leasing.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.00000U3 Pharma AG, located inMartinsried, Germany, isbiotechnology andpharmaceutical company. Thecompany manufactures cancerdrugs and other medicines. Thecompany specializes inoncology-focused research ledto the development of theoncology blockbustersHerceptin. It providesresearch and developmentservices for biotechnologicalproducts. It was founded inJuly 2001U3 Pharma AG, located in Martinsried, Germany, isbiotechnology and pharmaceutical company. The companymanufactures cancer drugs and other medicines. The companyspecializes in oncology-focused research led to thedevelopment of the oncology blockbusters Herceptin.